Research at ResMed

ResMed is dedicated to innovating and changing lives. We support and actively engage in research initiatives related to occupational health and safety.

As part of our commitment to deliver innovative therapies to patients across the globe, ResMed believes in the need to support ethical, independent clinical research, conducted by qualified third-party investigators.

ResMed Academy Online is designed to provide healthcare and medical equipment professionals with easy access to a variety of learning resources. Learners can enroll in online courses, complete learning activities, and track the progress of their online course completion in the comfort of their home or work.

ResMed is dedicated to innovating and changing lives. We support and actively engage in research initiatives related to type 2 diabetes.

ResMed is dedicated to innovating and changing lives. We support and actively engage in research initiatives related to peri-operative care.

ResMed is dedicated to innovating and changing lives. We support and actively engage in research initiatives related to sleep-disordered breathing.

The 5-year multicentre ORCADES study demonstrated both the efficacy and compliance of the Narval CC™ MRD.

Narval CC packs custom-made comfort into a small, lightweight device, making it easy for patients to be compliant and obtain high efficacy.

There’s a growing body of clinical research that demonstrates the efficacy and compliance of mandibular repositioning devices (MRDs) in treating obstructive sleep apnoea and snoring. The following clinical research papers demonstrate results in particular for ResMed’s Narval CC™ MRD.

ResMed is dedicated to innovating and changing lives. We support and actively engage in research initiatives related to cardiology.

People suffering from chronic obstructive pulmonary disease (COPD) - the third leading cause of death in the United States - may see their lives change thanks to a ResMed-sponsored clinical trial (NYSE: RMD) presented at the 2017 American Thoracic Society International Conference and published in the Journal of the American Medical Association (JAMA) today.

Choose your language.

ResMed presents data on Phase IV SERVE-HF study of Adaptive Servo-Ventilation therapy in central sleep apnea and chronic symptomatic heart failure at ESC Congress 2015.

New research released at European Respiratory Society (ERS) International Congress 2016 highlights the benefits of home non-invasive ventilation (NIV), with the potential to positively impact current practice and improve the lives of patients with COPD

Largest-ever analysis of patients with treatment-emergent central sleep apnea shows switching from CPAP to ASV significantly improves compliance.

People suffering from chronic obstructive pulmonary disease (COPD) - the third leading cause of death in the United States - may see their lives change thanks to a ResMed-sponsored clinical trial (NYSE: RMD) presented at the 2017 American Thoracic Society International Conference and published in the Journal of the American Medical Association (JAMA) today.